BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a Palo Alto-based biopharmaceutical company focused on medicines for genetic diseases. After a remarkable run that has roughly tripled the share price since its lead drug won approval, investors are now asking a straightforward question: can BBIO climb to the psychologically significant $100 level, which would mark its first foray into triple digits?
$100 is more than a round number. BridgeBio shares have traded in a 52-week range of roughly $42 to $93, so crossing $100 would require clearing the prior high and establishing a fresh record. It is also a level that appears repeatedly in sell-side research: RBC Capital, Jefferies, and H.C. Wainwright have each published or maintained $100 price targets, making it one of the most widely cited objectives for the stock.
BridgeBio's flagship product is Attruby (acoramidis), an oral near-complete stabilizer of transthyretin (TTR) used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive heart condition. The drug is now the company's primary revenue driver. In the second quarter of 2026, BridgeBio reported total revenue of roughly $243.7 million, with U.S. Attruby net product revenue of approximately $222.4 million, exceeding consensus estimates. Mizuho responded by raising its projected U.S. peak sales for Attruby to roughly $4 billion.
That momentum matters because BridgeBio is transitioning from a clinical-stage developer into a multi-product commercial business. Revenue is forecast to more than double this year, approaching $1 billion, yet the company still reports net losses and negative free cash flow as it funds an aggressive research pipeline.
Beyond Attruby, BridgeBio is advancing several late-stage programs that analysts argue are not fully reflected in the current share price:
If these assets secure approvals, BridgeBio could evolve from a one-product story into a diversified rare-disease franchise—a transition several analysts believe could justify a higher valuation.
Wall Street's posture toward BridgeBio remains broadly constructive. The consensus rating is a Buy, with average one-year price targets clustered between roughly $95 and $109, depending on the polling date. Individual targets range widely, from a low near $80 to a high of $157 from Barclays. Notably, several firms—including J.P. Morgan (now $111), Mizuho ($110), and Piper Sandler ($115)—have set targets above $100, suggesting the Street sees room for the stock to push through the milestone if execution holds.
The path to $100 is not without obstacles. BridgeBio's ATTR-CM franchise competes directly with Pfizer's tafamidis (Vyndamax/Vyndaqel) and with RNA-based "silencer" therapies from Alnylam. While analysts have argued that generic competition for tafamidis is unlikely before 2031–32, any unexpected shift in that legal landscape could pressure Attruby's outlook.
Financial risks also persist. The company is not yet profitable, carries a price-to-sales ratio that is elevated relative to historical norms, and has recorded meaningful insider selling over recent quarters—factors that warrant caution even amid strong top-line growth.
From a technical standpoint, the prior 52-week high in the low-$90s represents the most immediate supply zone. A decisive break above that area would open the door to $100. On the downside, the 200-day moving average near the low-$70s has served as a support level during pullbacks, and a sustained move below it could signal weakening momentum.
For traders monitoring BridgeBio or other names, AI Daily Buy/Sell Signals offers a data-driven way to stay on top of shifting conditions. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to uncover new opportunities, monitor existing positions, and identify changing market trends more efficiently. Exploring the tool can add another layer of discipline to any price-target watchlist.
A move to $100 for BridgeBio is plausible but far from assured. The strongest arguments in its favor are accelerating Attruby sales, a pipeline of late-stage candidates nearing regulatory decisions, and a consensus analyst target already above the milestone. The primary risks are continued losses and cash burn, competition in the ATTR-CM market, insider selling, and the inherent uncertainty of drug approvals. Investors should watch Attruby's quarterly sales trajectory, upcoming regulatory submissions and decisions, and the stock's ability to hold above its moving averages and clear the low-$90s resistance before $100 becomes reachable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with DYN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | -0.08% | ||
| DYN - BBIO | 45% Loosely correlated | -1.14% | ||
| AXON - BBIO | 44% Loosely correlated | +0.10% | ||
| ARRY - BBIO | 43% Loosely correlated | +1.54% | ||
| PMN - BBIO | 43% Loosely correlated | +1.19% | ||
| VKTX - BBIO | 42% Loosely correlated | -0.47% | ||
More | ||||